Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$14.53

+8.0%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$99.55M
EPS-70.5000
P/E Ratio-0.21
Earnings Date08/11/2026

vor

Common Stock

Last Annual Value

18.00K

3-Year CAGR

37%

5-Year CAGR

78%

10-Year CAGR

%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Common Stock

VOR · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
18.00K
37.0%35.1%N/A 
13.00K
-28.8%-2.8%20.6%
56.00K
1.9%11.8%-39.1%
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
9.00K
8.7%8.4%8.4%
12.00K
2.9%11.4%9.1%
2.00K
N/A-30.7%-7.7%
38.00K
12.1%33.4%N/A
1.88M
7.8%13.0%16.9%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
14.00K
5.3%N/AN/A
6.00K
14.5%-87.0%N/A
54.00K
70.0%37.5%12.3%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.525, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $14.525